These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 26116257)

  • 1. Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines.
    Pilishvili T; Bennett NM
    Vaccine; 2015 Nov; 33 Suppl 4():D60-5. PubMed ID: 26116257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumococcal Disease Prevention Among Adults: Strategies for the Use of Pneumococcal Vaccines.
    Pilishvili T; Bennett NM
    Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S383-90. PubMed ID: 26590438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Developments and Future Directions of Pneumococcal Vaccine Recommendations.
    Tromp KM; Campbell MW; Vazquez A
    Clin Ther; 2015 May; 37(5):928-34. PubMed ID: 25913921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theory and strategy for Pneumococcal vaccines in the elderly.
    Namkoong H; Ishii M; Funatsu Y; Kimizuka Y; Yagi K; Asami T; Asakura T; Suzuki S; Kamo T; Fujiwara H; Tasaka S; Betsuyaku T; Hasegawa N
    Hum Vaccin Immunother; 2016; 12(2):336-43. PubMed ID: 26406267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices.
    Matanock A; Lee G; Gierke R; Kobayashi M; Leidner A; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(46):1069-1075. PubMed ID: 31751323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years.
    Black CL; Williams WW; Warnock R; Pilishvili T; Kim D; Kelman JA
    MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(27):728-733. PubMed ID: 28704347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal conjugate vaccine use in adults.
    Isturiz RE; Schmoele-Thoma B; Scott DA; Jodar L; Webber C; Sings HL; Paradiso P
    Expert Rev Vaccines; 2016; 15(3):279-93. PubMed ID: 26651847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Tomczyk S; Bennett NM; Stoecker C; Gierke R; Moore MR; Whitney CG; Hadler S; Pilishvili T;
    MMWR Morb Mortal Wkly Rep; 2014 Sep; 63(37):822-5. PubMed ID: 25233284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):258-61. PubMed ID: 20224542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
    Isturiz R; Webber C
    Hum Vaccin Immunother; 2015; 11(7):1825-7. PubMed ID: 26076136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant.
    Musher DM; Rodriguez-Barradas MB
    Hum Vaccin Immunother; 2016; 12(2):331-5. PubMed ID: 26606172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jun; 62(25):521-4. PubMed ID: 23803961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Kobayashi M; Bennett NM; Gierke R; Almendares O; Moore MR; Whitney CG; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2015 Sep; 64(34):944-7. PubMed ID: 26334788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia.
    Sings HL
    Vaccine; 2017 Sep; 35(40):5406-5417. PubMed ID: 28602602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Oct; 61(40):816-9. PubMed ID: 23051612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program.
    Stoecker C; Kobayashi M; Matanock A; Cho BH; Pilishvili T
    Vaccine; 2020 Feb; 38(7):1770-1777. PubMed ID: 31889609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults?
    Weil-Olivier C; Gaillat J
    Vaccine; 2014 Apr; 32(18):2022-6. PubMed ID: 24565755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.